Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 7OTHER_GOV 1NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1

Conditions

Thyroid Neoplasms 31Thyroid Cancer, Papillary 26Pheochromocytoma 23Adenocarcinoma, Follicular 23Adrenocortical Carcinoma 21Neuroendocrine Tumors 20Carcinoma, Medullary 17Somatostatinoma 14Insulinoma 14Thyroid Carcinoma, Anaplastic 13Pituitary Neoplasms 13Paraganglioma 13Carcinoma, Neuroendocrine 12Glucagonoma 11Carcinoma, Renal Cell 11Parathyroid Neoplasms 10Pancreatic Neoplasms 10Gastrinoma 10Carcinoma, Non-Small-Cell Lung 10Carcinoma, Hepatocellular 10Head and Neck Neoplasms 9Colonic Neoplasms 9Carcinoma, Islet Cell 9Breast Neoplasms 9Small Cell Lung Carcinoma 8Sarcoma 8Neoplasms 8Rectal Neoplasms 7Multiple Endocrine Neoplasia Type 1 7Adrenal Gland Neoplasms 7

Interventions

antineoplaston AS 2-1 1antineoplaston A10 1Complementary Therapies 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Growth Hormone-Secreting Pituitary Adenoma × Endocrine × Clear all
NCT00003514 2013-07-10

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicEndocrine

Pituitary Neoplasms, Somatostatinoma, Carcinoma, Merkel Cell, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡